Arsenite induces oxidative injury in rat brain: Synergistic effect of iron: Annals of the New York academy of sciences

Annals of the New York Academy of Sciences

Volumn 1199, Issue , 2010, Pages 27-35

  Fan, Su Feng ^a   Chao, Pei Ling ^a   Lin, Anya Maan Yuh ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Arsenite; Iron; Neurotoxicity

Indexed keywords

ALPHA SYNUCLEIN; ARSENATE SODIUM; ARSENIC TRIOXIDE; BUTHIONINE SULFOXIMINE; CACODYLIC ACID; DOPAMINE; ESTRADIOL; GLUTATHIONE; HEME OXYGENASE 1; IRON; MELATONIN; METHANEARSONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN INJURY; CONFERENCE PAPER; DNA FRAGMENTATION; DRUG MECHANISM; ELECTROCHEMICAL ANALYSIS; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO CULTURE; LIPID PEROXIDATION; MALE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; WESTERN BLOTTING;

RATTUS;

EID: 77954018766     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05170.x     Document Type: Conference Paper

References (54)

1. Wright, R.O. & A. Baccarelli. 2007. Metals and neurotoxicology. J. Nutr. 137: 2809-2813.
2. Hall, A.H. 2002. Chronic arsenic poisoning. Toxicol. Lett. 128: 69-72.
3. Bolla-Wilson, K. & M.L. Bleecker. 1987. Neuropsychological impairment following inorganic arsenic exposure. J. Occup. Med. 29: 500-503.
4. Itoh, T. et al. 1990. The effect of arsenic trioxide on brain monoaminemetabolism and locomotor activity of mice. Toxicol. Lett. 54: 345-353.
5. Rodriguez, V.M., M.E. Jimenez-Capdeville & M. Giordano. 2003. The effects of arsenic exposure on the nervous system. Toxicol. Lett. 145: 1-18.
6. Soignet, S.L., P.Maslak&Z.G.Wang. 1998. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.N. Eng. J Med. 339: 1341-1348.
7. Shen, Z.X. et al. 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360.
8. Lin, C.C. et al. 2007. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest. New Drug 25: 77-84.
9. Kim, K.B. et al. 2005.Aphase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 104: 1687-1692.
10. Windebank, A.J. 1986. Specific inhibition ofmyelination by lead in vitro; Comparison with arsenic, thallium, and mercury. Exp Neurol. 94: 203-212.
11. Chao, Y.H. et al. 2008. Arsenite-induced cytotoxicity in DRG explants. Free Radic. Biol. Med. 44: 1553-1561.
12. Chao, P.L. et al. 2007. N-acetylcysteine attenuates arsenite-induced oxidative injury in DRG explants. Ann. N.Y. Acad. Sci. 1122: 276-288.
13. Lin, A.M.Y. et al. 2007. Endoplasmic reticulum stress is involved in arsenite-induced oxidative injury in rat brain. Toxicol. Appl. Pharmacol. 224: 138-146.
14. Lin, A.M.Y. et al. 2007. Melatonin attenuates arseniteinduced apoptosis in rat brain: involvement of mitochondrial and ER pathways and aggregation of-synuclein. J. Pineal Res. 43: 163-171.
15. Zecca, L. et al. 2004. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5: 863-873.
16. Dexter, D.T. et al. 1989. Increased nigral iron content and alteration in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52: 1830-1836.
17. Floyd, R.A. & J.M. Carney. 1992. Free radicals damage to protein and DNA: mechanisms involved and relevant observation on brain undergoing oxidative stress. Ann. Neurol. 32: S22-S27.
18. Mecocci, P. et al. 1993. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 34: 609-616.
19. Halliwell, B. & J.M. Gutteridge. 1984. Oxygen toxicity, oxygen radicals, transition metals and diseases. J. Biochem. 219: 1-14.
20. Gotz, M.E. et al. 2004. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N.Y. Acad. Sci. 1012: 193-208.
21. Lotharius, J. & P. Brundin. 2002. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Genet. 11: 395-407.
22. Lin, A.M.Y. & L.T. Ho. 2000.Melatonin suppresses ironinduced neurodegeneration in rat brain. Free Radic. Biol. Med. 28: 904-911.
23. Lin, A.M.Y. 2001. Coexistence of zinc and iron augmented oxidative injuries in the nigrostriatal dopaminergic system of SD rats. Free Radic. Biol. Med. 30: 225-231.
24. Sengstock, G.J. et al. 1997. Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration. Biol. Trace. Elem. Res. 58: 177-195.
25. Domingo, J.L. 2006. Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents. Alzheimers Dis. 10: 331-341.
26. Rodriguez, V.M. et al. 1998. Effects of oral exposure to mining waste on in vivo dopamine release from rat striatum. Environ. Health Perspect. 106: 487-491.
27. Roth, J.A. & M.D. Garrick. 2003. Iron interactions and other biological reactions mediating the physiological and toxic actions of manganese. Biochem Pharmacol. 66: 1-13.
28. Chandra, A.V. et al. 1981. Behavioral and neurochemical changes in rats simultaneously exposed to manganese and lead. Arch. Toxicol. 49: 49-56.
29. Kalia, K., S.V. Chandra & P.N. Viswanathan. 1984. Effect of54Mn and lead interaction on their bindingwith tissue proteins: in vitro studies. Ind. Health 22: 207-218.
30. Mejia, J.J. et al. 1997. Effects of lead-arsenic combined exposure on central monoaminergic systems. Neurotoxicol. Teratol. 19: 489-497.
31. Kikugawa, K. et al. 1989. Fluorescent and cross-linked proteins formed by free radical and aldehyde species generated during lipid peroxidation. Adv. Exper. Med. Biol. 266: 345-356.
32. Paxinos, G. & C.Watson. 1986. The Rat Brain in Stereotaxic Coordinates. Academic Press. New York.
33. Chiueh, C.C. et al. 1983. 6-fluorocatecholamines as false adrenergic neurotransmitters. J. Pharmacol. Exp. Ther. 225: 529-533.
34. Griffith, O.W. 1980. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106: 207-212.
35. Sambrook, J., E.F. Fritch & T. Maniatis. Analysis and cloning of eukaryotic genomic DNA. In Molecular Cloning. Ford, N., C. Nolan&M. Ferguson, Eds.: 9.16-9.19. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NT.
36. Bernstam, L. & J. Nriagu. 2000. Molecular aspects of arsenic stress. J. Toxicol. Environ. Health 3: 293-322.
37. Chattopadhyay, S. et al. 2002. Apoptosis and necrosis in developing brain cells due to arsenic toxicity and protection with antioxidants. Toxicol. Lett. 136: 665-676.
38. Guidarelli, A. et al. 2005. Role of Bcl-2 in the arachidonate-mediated survival signaling preventing mitochondrial permeability transition-dependent U937 cell necrosis induced by peroxynitrite. Free Radic. Biol. Med. 39: 1638-1649.
39. Chen, Y.C., S.Y. Lin-Shiau & J.K. Lin. 1998. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J. Cell. Physiol. 177: 324-333.
40. Garcia-Chavez, E. et al. 2003. Arsenite-induced formation of hydroxyl radical in the striatum of awake rats. Brain Res. 976: 82-89.
41. Bau, D.T. et al. 2002. Oxidative DNA adducts and DNAprotein cross-links are the major DNA lesions induced by arsenite. Environ. Health Persp. 110: 753-756.
42. Bernstam, L. & J. Nriagu. 2000. Molecular aspects of arsenic stress. J. Toxicol. Environ. Health 3: 293-322.
43. Ramanathan, K. et al. 2005. Ascorbic acid and alphatocopherol as potent modulators of apoptosis on arsenic induced toxicity in rats. Toxicol. Lett. 156: 297-306.
44. Lantz, R.C. et al. 1994. Effect of arsenic exposure on alveolar macrophage function. I. Effect of soluble As (III) and As (V). Environ. Res. 67: 183-195.
45. Perry, T.L., D.V. Godin & A. Hansen. 1982. Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci. Lett. 33: 305-310.
46. Sofic, E. et al. 1992. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142: 128-130.
47. de la Torre, M.R. et al. 1996. Human aging brain disorders: role of antioxidant enzymes. Neurochem. Res. 21: 885-888.
48. Sakurai, T. et al. 2002. A major human arsenic metabolite, dimethylarsinic acid, requires reduced glutathione to induce apoptosis. Chem. Res. Toxicol. 15: 629-637.
49. Yang, C.H. et al. 1999. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br. J. Cancer 81: 796-799.
50. Lin, A.M.Y., C.F. Chen & L.T. Ho. 2002. Neuroprotective effect of intermittent hypoxia on iron-induced oxidative injury in rat brain. Exp. Neurol. 176: 328-335.
51. Ahmad, S., K.T. Kitchin & W.R. Cullen. 2000. Arsenic species that cause release of iron from ferritin and generation of activated oxygen. Arch. Biochem. Biophys. 382: 195-202.
52. Holtz,W.A.&K.L.O'Malley. 2003. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J. Biol. Chem. 278: 19367-19377.
53. Imai, Y. et al. 2001. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105: 891-902.
54. Vekrellis, K., H.J. Rideout & L. Stefanis. 2004. Neurobiology of alpha-synuclein. Mol. Neurobiol. 30: 1-21.